These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6130953)

  • 1. Kinetics and metabolism of (+)-, (-)- and (+/-)-bufuralol.
    Francis RJ; East PB; Larman J
    Eur J Clin Pharmacol; 1982; 23(6):529-33. PubMed ID: 6130953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of renal failure on the hepatic clearance of bufuralol in man.
    Balant L; Francis RJ; Tozer TN; Marmy A; Tschopp JM; Fabre J
    J Pharmacokinet Biopharm; 1980 Oct; 8(5):421-38. PubMed ID: 6114166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
    Dayer P; Leemann T; Küpfer A; Kronbach T; Meyer UA
    Eur J Clin Pharmacol; 1986; 31(3):313-8. PubMed ID: 2878813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The genetic control of bufuralol metabolism in man.
    Dayer P; Balant L; Courvoisier F; Kupfer A; Kubli A; Gorgia A; Fabre J
    Eur J Drug Metab Pharmacokinet; 1982; 7(1):73-7. PubMed ID: 6121708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.
    Prueksaritanont T; Dwyer LM; Cribb AE
    Biochem Pharmacol; 1995 Oct; 50(9):1521-5. PubMed ID: 7503805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic and pharmacokinetic studies on bufuralol in man.
    Pringle TH; Francis RJ; East PB; Shanks RG
    Br J Clin Pharmacol; 1986 Nov; 22(5):527-34. PubMed ID: 2878678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.
    Boobis AR; Murray S; Hampden CE; Davies DS
    Biochem Pharmacol; 1985 Jan; 34(1):65-71. PubMed ID: 3966916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enantioselective and diastereoselective hydroxylation of bufuralol. Absolute configuration of the 7-(1-hydroxyethyl)-2-[1-hydroxy-2-(tert-butylamino)ethyl]benzofurans, the benzylic hydroxylation metabolites.
    Weerawarna SA; Geisshüsler SM; Murthy SS; Nelson WL
    J Med Chem; 1991 Oct; 34(10):3091-7. PubMed ID: 1681107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
    Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
    Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.
    Dayer P; Balant L; Kupfer A; Striberni R; Leemann T
    Eur J Clin Pharmacol; 1985; 28(3):317-20. PubMed ID: 2861095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
    Mankowski DC
    Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.
    Gut J; Gasser R; Dayer P; Kronbach T; Catin T; Meyer UA
    FEBS Lett; 1984 Aug; 173(2):287-90. PubMed ID: 6146537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
    Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
    Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential roles of cytochromes P450 2D1, 2C11, and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes.
    Mimura M; Yamazaki H; Sugahara C; Hiroi T; Funae Y; Shimada T
    Biochem Pharmacol; 1994 Jun; 47(11):1957-63. PubMed ID: 7912070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s.
    Narimatsu S; Takemi C; Kuramoto S; Tsuzuki D; Hichiya H; Tamagake K; Yamamoto S
    Chirality; 2003 May; 15(4):333-9. PubMed ID: 12666241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphic metabolism of beta-adrenoceptor antagonists.
    Silas JH; Lennard MS; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):11S-19S. PubMed ID: 6146335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
    Lennard MS; Tucker GT; Woods HF
    Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
    McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
    Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence requirements for cytochrome P-450IID1 catalytic activity. A single amino acid change (Ile380 Phe) specifically decreases Vmax of the enzyme for bufuralol but not debrisoquine hydroxylation.
    Matsunaga E; Zeugin T; Zanger UM; Aoyama T; Meyer UA; Gonzalez FJ
    J Biol Chem; 1990 Oct; 265(28):17197-201. PubMed ID: 1976628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectrofluorometric determination of bufuralol in blood and urine.
    de Silva JA; Meyer JC; Puglisi CV
    J Pharm Sci; 1976 Aug; 65(8):1230-33. PubMed ID: 10418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.